A Clinicobiological Database in Metastatic Digestive Cancers
キーワード
概要
説明
Digestive cancers account for 30% of all cancers. The most common of these colorectal cancer (CRC) is the third most common cause of cancer in the world.
In the metastatic phase, patients with digestive cancers generally benefit from medical treatment based on cytotoxic chemotherapy, which can be combined with targeted therapy in certain locations. Their use is based on demonstrating a significant improvement in the overall survival of patients.
However, the therapeutic choice and follow-up of these treatments as a the first line treatment and beyond remain difficult given a cruel lack of biomarkers capable of predicting the response to these different molecules upstream but also usable during treatment to evaluate their efficacy or identify the development of secondary resistance mechanisms.
Indeed, the only biomarkers currently validated and used before the initiation of anti-cancer treatment to stratify patients are:
- the search for mutations in Kirsten rat sarcoma viral oncogene homolog (KRAS) and neuroblastoma rat sarcoma viral oncogene (NRAS) oncogenes as predictive factors for non-response to anti-Epidermal Growth Factor receptor (EGFR) in colorectal adenocarcinomas.
- the search for overexpression of the human epidermal growth factor (HER2) receptor to introduce trastuzumab treatment in esophageal adenocarcinomas.
In addition, they are conventionally determined from tumor tissue, which requires an invasive biopsy or surgical sampling that is difficult to repeat over time.
In this context, it seems essential to us to identify new parameters allowing a better personalization of anti-cancer treatments, by favouring blood biomarkers that have the advantage of being evaluated in a minimally invasive manner and therefore be repeated to be able to judge tumor dynamics.
To this end, we propose the creation of a collection of samples that will be collected before and then under treatment in patients with digestive adenocarcinoma in the 1st and 2nd metastatic line and which, depending on scientific progress, can be used for research projects aimed at developing tailored patient management strategies.
日付
| 最終確認済み: | 05/31/2019 |
| 最初に提出された: | 06/04/2019 |
| 提出された推定登録数: | 06/04/2019 |
| 最初の投稿: | 06/05/2019 |
| 最終更新が送信されました: | 07/04/2019 |
| 最終更新日: | 07/08/2019 |
| 実際の研究開始日: | 09/11/2016 |
| 一次完了予定日: | 03/31/2021 |
| 研究完了予定日: | 03/31/2026 |
状態または病気
介入/治療
Other: Biological collection
段階
アームグループ
| 腕 | 介入/治療 |
|---|---|
| Experimental: Biological collection For all the patients include in the study :
- Blood samples collected at different times : Before treatment, during treatment (approximately every other month) through the end of treatment
In parallel to this biological collection, standardized clinical data will be entered into a database | Other: Biological collection - Blood samples collected at different times : Before treatment, during treatment (approximately every other month) through the end of treatment |
適格基準
| 研究の対象となる年齢 | 18 Years に 18 Years |
| 研究に適格な性別 | All |
| 健康なボランティアを受け入れる | はい |
| 基準 | Inclusion Criteria: 1. Male or female ≥ 18 years old 2. Histological documentation of adenocarcinoma of the colon or rectum, small intestine, pancreas, stomach, bile duct, oesophagus 3. Patient who will receive a first or second line metastatic chemotherapy and/or targeted therapy 4. Informed consent form (ICF) signed Exclusion Criteria: 1. Male or female < 18 years old 2. Non-adenocarcinoma histological type 3. Patient already undergoing specific treatment (chemotherapy and/or targeted therapy) in 1st or 2nd metastatic line 4. Pregnant and/or breastfeeding woman 5. Patient not affiliated to a social security system 6. Patient whose regular follow-up is impossible for psychological, family, social or geographical reasons 7. Patient who is included in a Phase I-II therapeutic trial modifying usual management and involving additional and specific blood samples |
結果
主な結果の測定
1. Number of clinical risk factors for metastatic digestive cancer [Until the study completion : 54 months]
2. Number of biological risk factors for metastatic digestive cancer [Until the study completion : 54 months]
